T-Therapeutics announced an oversubscribed USD 133 million Series B to move two T cell receptor programmes into clinical development. Advent Life Sciences and British Business Bank co led the financing, with Johnson and Johnson Innovation, Samsara BioCapital, M Ventures, Lilly and existing shareholders participating. The Cambridge biotechnology company uses its OpTiMus platform to identify fully human receptors for targets inside cells. Chief executive Theodora Harold says the funding supports oncology and autoimmune programmes through clinical proof of concept. The company also appointed Kirsty Crame as chief development officer. Therapeutic potential described in the announcement remains preclinical and should not be read as evidence of patient benefit.
T-Therapeutics raises USD 133m for clinical programmes
Advent Life Sciences and British Business Bank co lead the Series B

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


